1. RBM partners plan to create a forum for dialogue with the manufacturers of ACTs. Such a forum is key in facilitating the sharing of information on needs and capacities as well as bottlenecks in ensuring access to these vital products.
2. WHO should coordinate the forecasting of needs for ACTs, due to the implications for manufacturers in sourcing APIs and requirements for raw materials to be extracted from natural sources, linked with agricultural production plans.
3. Manufacturers of ACTs should be encouraged to extend their stability testing protocols to include evaluation of products under tropical conditions (Climatic Zone IV as -described under WHO guidelines for GMP).
4. The pre-qualification of antimalarials should be extended to include the sources of active pharmaceutical ingredients (API) for artemisinin derivatives and their recommended partner drugs.
5. Safety and efficacy data on the WHO recommended ACTs should be collated and disseminated to national regulatory authorities to facilitate the review and registration of these products.
6. Comparator products for bio-equivalence studies with the ACTs should be established. A process for this activity is established in WHO/EDM and funding now needs to be identified.